Tonghe Pharmaceutical announced that the company's shareholding company Hangzhou Boya Biomedical Co., Ltd. plans to increase capital by 15.00 million yuan, introduce new investors Yao Xiaohua, Tong Shaorong, and Zhou Xiaogang, and jointly increase capital with existing shareholders Ji Huilan and Li Xuan. Among them, Yao Xiaohua is an affiliate of Huang Guojun, the company's director and deputy general manager, and has pledged 5 million yuan. After the capital increase, the shareholding ratio was 2.4390%. After comprehensive consideration, the company decided to relinquish the priority subscription rights for this capital increase. This matter constitutes a related transaction and does not constitute a major asset restructuring. After the capital increase is completed, the company's shareholding ratio in Hangzhou Boya will be reduced from 24.9285% to 23.1043%, which will not cause changes in the scope of consolidated statements and will not have a significant impact on the company's finances and operations.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.